EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer

Dennis J Slamon iD, Véronique Diéras iD, Hope S Rugo iD, Nadia Harbeck iD, Seock-Ah Im iD, Karen A Gelmon iD, Oleg N Lipatov, Janice M Walshe iD, Miguel Martin iD, Mariana Chavez-MacGregor iD, Eustratios Bananis, Eric Gauthier iD und 3 weitere

Journal of Clinical Oncology · 20.03.2024 · 42 (9) · 994-1000

DOI: 10.1200/jco.23.00137 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.03.2024. Verfasst von Dennis J Slamon und 14 weiteren Autor:innen. Beteiligte Einrichtung: David Geffen School of Medicine at University of California Los Angeles, Santa Monica, CA. Hauptthemen laut MEDLINE: Breast Neoplasms, Piperazines, Pyridines. Die Arbeit wurde bisher 208-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. PALOMA-2 demonstrated statistically and clinically significant improvement in progression-free survival with palbociclib plus letrozole versus placebo plus letrozole in estrogen receptor–positive/human epidermal growth factor receptor 2–negative (ER+/HER2–) advanced breast cancer (ABC). Here, we report results for the secondary end point overall survival (OS). Postmenopausal women (N = 666) with ER+/HER2– ABC without previous systemic therapy for ABC were randomly assigned 2:1 to palbociclib plus letrozole or placebo plus letrozole. After a median follow-up of 90.1 months, 405 deaths were observed and 155 patients were known to be alive. The median OS was 53.9 months (95% CI, 49.8 to 60.8) with palbociclib plus letrozole versus 51.2 months (95% CI, 43.7 to 58.9) with placebo plus letrozole (hazard ratio [HR], 0.96 [95% CI, 0.78 to 1.18]; stratified one-sided P = .34). An imbalance in the number of patients with unknown survival outcome between the treatment arms (13.3% v 21.2%, respectively) limited interpretation of OS results. With recovered survival data, the median OS was 53.8 (95% CI, 49.8 to 59.2) versus 49.8 months (95% CI, 42.3 to 56.4), respectively (HR, 0.92 [95% CI, 0.76 to 1.12]; one-sided P = .21). OS was not significantly improved with palbociclib plus letrozole compared with placebo plus letrozole.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsPiperazinesPyridinesHumansFemaleLetrozoleErb-b2 Receptor Tyrosine KinasesAntineoplastic Combined Chemotherapy Protocols

Substanzen

LetrozoleErb-b2 Receptor Tyrosine KinasesPiperazinesPyridinespalbociclib

Autor:innen und Institutionen

  • David Geffen School of Medicine at University of California Los Angeles, Santa Monica, CA.
  • Centre Eugène Marquis, Rennes Cedex, France.
  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.
  • Brustzentrum, Frauenklinik and CCC Munich, LMU University Hospital, Munich, Germany.
  • Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • BC Cancer, Vancouver, BC, Canada.

ORCID-Profile: Dennis J Slamon, Véronique Diéras, Hope S Rugo, Nadia Harbeck, Seock-Ah Im, Karen A Gelmon, Janice M Walshe, Miguel Martin, Mariana Chavez-MacGregor, Eric Gauthier, Dongrui R Lu, Richard S Finn

Zitieren

APA

Slamon, D. J., Diéras, V., Rugo, H. S., Harbeck, N., Im, S. A., Gelmon, K. A., Lipatov, O. N., Walshe, J. M., Martin, M., Chavez-MacGregor, M., Bananis, E., Gauthier, E., Lu, D. R., Kim, S., & Finn, R. S. (2024). Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer. Journal of Clinical Oncology, 42(9), 994-1000. https://doi.org/10.1200/jco.23.00137

Vancouver

Slamon DJ, Diéras V, Rugo HS, Harbeck N, Im SA, Gelmon KA, et al. Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer. Journal of Clinical Oncology. 2024;42(9):994-1000. doi:10.1200/jco.23.00137

BibTeX
@article{Slamon2024,
  author = {Slamon, Dennis J and Diéras, Véronique and Rugo, Hope S and Harbeck, Nadia and Im, Seock-Ah and Gelmon, Karen A and Lipatov, Oleg N and Walshe, Janice M and Martin, Miguel and Chavez-MacGregor, Mariana and Bananis, Eustratios and Gauthier, Eric and Lu, Dongrui R and Kim, Sindy and Finn, Richard S},
  title = {Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {9},
  pages = {994--1000},
  doi = {10.1200/jco.23.00137}
}
Kostenlos starten →